{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:23:46Z","timestamp":1795119826936,"version":"4.10.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1389"],"award-info":[{"award-number":["SFB1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1389"],"award-info":[{"award-number":["SFB1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1389"],"award-info":[{"award-number":["SFB1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1389"],"award-info":[{"award-number":["SFB1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1389"],"award-info":[{"award-number":["SFB1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1389"],"award-info":[{"award-number":["SFB1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1389"],"award-info":[{"award-number":["SFB1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1389"],"award-info":[{"award-number":["SFB1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The clonal glioma driver mutation\n                    <jats:italic>IDH1<\/jats:italic>\n                    <jats:sup>R132H<\/jats:sup>\n                    gives rise to a major histocompatibility class II-restricted neoepitope. A multicenter, first-in-human phase 1 trial met its prespecified primary endpoints by demonstrating safety and immunogenicity of an IDH1-R132H peptide vaccine (IDH1-vac) integrated into standard of care in 33 participants with newly diagnosed grade III and IV (World Health Organization classification 2007) IDH1-R132H\n                    <jats:sup>+<\/jats:sup>\n                    astrocytomas (NOA16). Here we report on the clinical and immunological long-term follow-up of this trial as secondary and translational endpoints. The 8-year progression-free and overall survival (OS) rates were 0.42 (confidence interval (CI): 0.24\u20130.59) and 0.66 (CI: 0.46\u20130.79), respectively. For participants with grade IV astrocytoma, median OS was 106.1\u2009months (CI: 39.6\u2013not estimable (NE)), comparing favorably to the published median OS in this population ranging from 31.6\u201356.4\u2009months. Within the responder group, sustained antibody responses to IDH1-R132H were associated with a favorable long-term clinical course. IDH1-vac-induced T cell responses were detected in the inflamed brain lesion of an IDH1-vac-associated pseudoprogression, whereas no IDH1-vac-induced T cells were found in participants with early progressive disease. The favorable long-term outcome of the NOA16 cohort supports investigating IDH1-vac in persons with newly diagnosed grade 3 and 4 (World Health Organization classification 2021)\n                    <jats:italic>IDH<\/jats:italic>\n                    -mutant astrocytomas in a randomized phase 2 trial (ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02454634\" ext-link-type=\"uri\">NCT02454634<\/jats:ext-link>\n                    ).\n                  <\/jats:p>","DOI":"10.1038\/s43018-026-01199-y","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:54:24Z","timestamp":1782914064000},"page":"1300-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-7574","authenticated-orcid":false,"given":"Lukas","family":"Bunse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-3266","authenticated-orcid":false,"given":"Katharina","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"Lanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Suwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O.","family":"Breckwoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Harting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-2059","authenticated-orcid":false,"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Misch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Krex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Denk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-7391","authenticated-orcid":false,"given":"Juliane","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim P.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-540X","authenticated-orcid":false,"given":"Andreas","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-1509","authenticated-orcid":false,"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-4269","authenticated-orcid":false,"given":"Theresa","family":"Bunse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-8782","authenticated-orcid":false,"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Poschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-887X","authenticated-orcid":false,"given":"Michael","family":"Platten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1199_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. 389, 589\u2013601 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1199_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474\u2013478 (2012).","journal-title":"Nature"},{"key":"1199_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.1236062","volume":"340","author":"D Rohle","year":"2013","unstructured":"Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626\u2013630 (2013).","journal-title":"Science"},{"key":"1199_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature13387","volume":"512","author":"T Schumacher","year":"2014","unstructured":"Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324\u2013327 (2014).","journal-title":"Nature"},{"key":"1199_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","volume":"592","author":"M Platten","year":"2021","unstructured":"Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592, 463\u2013468 (2021).","journal-title":"Nature"},{"key":"1199_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02662-1","volume":"147","author":"M Weller","year":"2024","unstructured":"Weller, M. et al. Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma. Acta Neuropathol. 147, 11 (2024).","journal-title":"Acta Neuropathol."},{"key":"1199_CR8","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/neuonc\/noae009","volume":"26","author":"K Galbraith","year":"2024","unstructured":"Galbraith, K. et al. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A\/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas. Neuro Oncol. 26, 1042\u20131051 (2024).","journal-title":"Neuro Oncol."},{"key":"1199_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13233","volume":"34","author":"T Kling","year":"2024","unstructured":"Kling, T. et al. Refinement of prognostication for IDH-mutant astrocytomas using DNA methylation-based classification. Brain Pathol. 34, e13233 (2024).","journal-title":"Brain Pathol."},{"key":"1199_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100214","volume":"6","author":"M Platten","year":"2021","unstructured":"Platten, M., Bunse, L. & Wick, W. Emerging targets for anticancer vaccination: IDH. ESMO Open 6, 100214 (2021).","journal-title":"ESMO Open"},{"key":"1199_CR11","doi-asserted-by":"publisher","first-page":"e012216","DOI":"10.1136\/jitc-2025-012216","volume":"13","author":"K Lindner","year":"2025","unstructured":"Lindner, K. et al. ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancer. J. Immunother. Cancer 13, e012216 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1199_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011070","volume":"13","author":"H Zelba","year":"2025","unstructured":"Zelba, H. et al. In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination. J. Immunother. Cancer 13, e011070 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1199_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"1199_CR14","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1200\/JCO.21.02929","volume":"41","author":"SL Hervey-Jumper","year":"2023","unstructured":"Hervey-Jumper, S. L. et al. Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma. J. Clin. Oncol. 41, 2029\u20132042 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1199_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/CCO.0000000000000478","volume":"30","author":"M Friedrich","year":"2018","unstructured":"Friedrich, M., Bunse, L., Wick, W. & Platten, M. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. Curr. Opin. Oncol. 30, 368\u2013374 (2018).","journal-title":"Curr. Opin. Oncol."},{"key":"1199_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl6173","volume":"385","author":"MJ Wu","year":"2024","unstructured":"Wu, M. J. et al. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science 385, eadl6173 (2024).","journal-title":"Science"},{"key":"1199_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1101\/gad.294991.116","volume":"31","author":"NM Amankulor","year":"2017","unstructured":"Amankulor, N. M. et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 31, 774\u2013786 (2017).","journal-title":"Genes Dev."},{"key":"1199_CR18","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 127, 1425\u20131437 (2017).","journal-title":"J. Clin. Invest."},{"key":"1199_CR19","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1056\/NEJMcibr2410562","volume":"391","author":"M Platten","year":"2024","unstructured":"Platten, M. & Bunse, L. Heating up IDH-mutant gliomas. N. Engl. J. Med. 391, 2170\u20132172 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1199_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/neuonc\/noab266","volume":"24","author":"L Bunse","year":"2022","unstructured":"Bunse, L. & Platten, M. How mutant isocitrate dehydrogenase orchestrates immune cells. Neuro Oncol. 24, 210\u2013212 (2022).","journal-title":"Neuro Oncol."},{"key":"1199_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","volume":"2","author":"M Friedrich","year":"2021","unstructured":"Friedrich, M. et al. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat. Cancer 2, 723\u2013740 (2021).","journal-title":"Nat. Cancer"},{"key":"1199_CR22","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","volume":"24","author":"L Bunse","year":"2018","unstructured":"Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat. Med. 24, 1192\u20131203 (2018).","journal-title":"Nat. Med."},{"key":"1199_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent, M. J. et al. Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 22, 813\u2013823 (2021).","journal-title":"Lancet Oncol."},{"key":"1199_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00401-021-02291-6","volume":"141","author":"CMS Tesileanu","year":"2021","unstructured":"Tesileanu, C. M. S. et al. Non-IDH1-R132H IDH1\/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol. 141, 945\u2013957 (2021).","journal-title":"Acta Neuropathol."},{"key":"1199_CR25","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-09-0715","volume":"15","author":"S Nobusawa","year":"2009","unstructured":"Nobusawa, S., Watanabe, T., Kleihues, P. & Ohgaki, H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 15, 6002\u20136007 (2009).","journal-title":"Clin Cancer Res."},{"key":"1199_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00401-017-1690-1","volume":"133","author":"M Pekmezci","year":"2017","unstructured":"Pekmezci, M. et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 133, 1001\u20131016 (2017).","journal-title":"Acta Neuropathol."},{"key":"1199_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221109650","volume":"21","author":"J Stewart","year":"2022","unstructured":"Stewart, J. et al. Pattern of recurrence of glioblastoma versus grade 4 IDH-mutant astrocytoma following chemoradiation: a retrospective matched-cohort analysis. Technol. Cancer Res. Treat. 21, 15330338221109650 (2022).","journal-title":"Technol. Cancer Res. Treat."},{"key":"1199_CR28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/s41379-021-00778-x","volume":"34","author":"QH Wong","year":"2021","unstructured":"Wong, Q. H. et al. Molecular landscape of IDH-mutant primary astrocytoma grade IV\/glioblastomas. Mod. Pathol. 34, 1245\u20131260 (2021).","journal-title":"Mod. Pathol."},{"key":"1199_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-022-00184-x","volume":"4","author":"L Bunse","year":"2022","unstructured":"Bunse, L. et al. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. Neurol. Res. Pract. 4, 20 (2022).","journal-title":"Neurol. Res. Pract."},{"key":"1199_CR30","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ccell.2023.09.013","volume":"41","author":"B Zhao","year":"2023","unstructured":"Zhao, B., Kilian, M., Bunse, T., Platten, M. & Bunse, L. Tumor-reactive T helper cells in the context of vaccination against glioma. Cancer Cell 41, 1829\u20131834 (2023).","journal-title":"Cancer Cell"},{"key":"1199_CR31","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-023-02555-6","volume":"29","author":"N Grassl","year":"2023","unstructured":"Grassl, N. et al. A H3K27M-targeted vaccine in adults with diffuse midline glioma. Nat. Med. 29, 2586\u20132592 (2023).","journal-title":"Nat. Med."},{"key":"1199_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi9091","volume":"10","author":"T Boschert","year":"2024","unstructured":"Boschert, T. et al. H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient. Sci. Adv. 10, eadi9091 (2024).","journal-title":"Sci. Adv."},{"key":"1199_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ads0449","volume":"10","author":"L Bunse","year":"2025","unstructured":"Bunse, L., Bunse, T., Kilian, M., Quintana, F. J. & Platten, M. The immunology of brain tumors. Sci. Immunol. 10, eads0449 (2025).","journal-title":"Sci. Immunol."},{"key":"1199_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"1199_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"1199_CR36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald, D. R., Cascino, T. L., Schold, S. C. Jr & Cairncross, J. G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277\u20131280 (1990).","journal-title":"J. Clin. Oncol."},{"key":"1199_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41587-024-02161-y","volume":"43","author":"CL Tan","year":"2025","unstructured":"Tan, C. L. et al. Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy. Nat. Biotechnol. 43, 134\u2013142 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1199_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469\u2013474 (2018).","journal-title":"Nature"},{"key":"1199_CR39","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00401-015-1519-8","volume":"131","author":"F Sahm","year":"2016","unstructured":"Sahm, F. et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 131, 903\u2013910 (2016).","journal-title":"Acta Neuropathol."}],"updated-by":[{"DOI":"10.1038\/s43018-026-01227-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000}}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01199-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01199-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01199-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:08:29Z","timestamp":1787321309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01199-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01199-y","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s43018-026-01227-x","URL":"https:\/\/doi.org\/10.1038\/s43018-026-01227-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.S. is a cofounder and shareholder of Heidelberg Epignostix. D.K. has received honoraria for lectures, consultation or advisory board participation from Novocure and BrainLab. A.v.D. holds patents EP15158660 (\u2018DNA methylation-based method for classifying tumor species\u2019), EP09015511 (\u2018Means and methods for diagnosing cancer using an antibody that specifically binds to BRAF-V600E\u2019) and EP09015511 (\u2018Methods for diagnosis and prognosis of a brain tumor; IDH H09 antibody\u2019), receives royalties from Dianova for IDHR132H AB H09 and Roche for BRAF-V600E AB VE1 and is a cofounder and owner of the company Heidelberg Epignostix. T.B., W.W. and M.P. are inventors and patent holders for EP2800580B1 (\u2018Peptides for use in treating or diagnosing IDH1-R132H-positive cancers\u2019). G.T. has served on advisory boards (Bayer, Boehringer Ingelheim, CureVac, Miltenyi Biomedicine, Novocure and Servier), as a consultant (Bayer, Boehringer Ingelheim and CureVac), as a steering committee member in noninterventional trials (Bayer and Novocure) and as a speaker (Novocure and Servier). M.P. is the founder of Tcelltech.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}